Professional paper

Ramipril in the treatment of high-risk cardiovascular patients

Saša Žikić ; Krka, d. d., Novo mesto, Slovenia
Mateja Grošelj ; Krka, d. d., Novo mesto, Slovenia
Breda Barbič Žagar orcid.org/0000-0002-1173-7361 ; Krka, d. d., Novo mesto, Slovenia

Abstract

Risk factors are conditions or habits that increase the risk of developing a disease. Risk factors such as hypertension, smoking, high cholesterol and diabetes contribute significantly to the development of cardiovascular diseases. Cardiovascular diseases are the major cause of mortality and morbidity in industrialised countries. Angiotensin-converting enzyme inhibitors reduce the risk of cardiovascular events in patients at all levels of risk. Numerous clinical studies have already proved the efficacy and safety of ramipril in hypertension treatment. The results of the HOPE study also demonstrated clear vascular and metabolic benefits of ramipril therapy. These benefits were consistent regardless of the patients’ risk factors or additional treatments. Clinical studies with Krka’s ramipril confirmed its efficacy in achieving target blood pressure levels and demonstrated its various additional benefits in high-risk patients.

Keywords

hypertension; risk factors; ramipril

Hrčak ID:

84926

URI

https://hrcak.srce.hr/84926

Publication date:

23.7.2012.

Article data in other languages: croatian

Visits: 2.037 *